TMTrina Mouchahoir

Trina Mouchahoir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Trina Mouchahoir has a total of 116 co-authors. Here are the top co-authors by number of shared publications:

  • John E. Schiel

    National Institute of Standards and Technology, 100 Bureau Dr, Gaithersburg, Maryland 20899, United States

    3 shared publications
  • Aaron Ammerman

    AbbVie, 1000 Gateway Blvd, South San Francisco, California 94080, United States

    2 shared publications
  • Ahmet Cansizoglu

    Charles River Laboratories, 8 Henshaw Street, Shrewsbury, Massachusetts 01801, United States

    2 shared publications
  • Albrecht Gruhler

    Novo Nordisk, Novo Nordisk Park, Måløv 2760, Denmark

    2 shared publications
  • Alexander J. Veach

    Amgen, One Amgen Center Dr, Thousand Oaks, California 91320, United States

    2 shared publications
  • Anders Lund

    Sanofi, 1 The Mountain Rd, Framingham, Massachusetts 01701, United States

    2 shared publications

Latest Publications

  • ShortCut RNase III is capable of digesting single mRNA transcripts into < 10 nucleotide products

    by Kyle J. Tynan, Mark S. Lowenthal, Karndeep Singh, Trina Mouchahoir, Daniel Hunter, Karen W. Phinney


  • Humanized monoclonal antibody IgG1k, NISTmAb RM 8671 summary of 5 year stability verification (5YSV)

    by Katharina Yandrofski, John E Schiel, Trina Mouchahoir, Srivalli Telikepalli, Dean C Ripple, Karen W Phinney, John P Marino, Paul C DeRose, N Alan Heckert

    NISTmAb RM 8671 is an IgG1k monoclonal antibody that has been extensively characterized and released as the first of its kind biopharmaceutical reference material in 2016. This material was intended primarily for use in evaluating the performance of methods for determining physicochemical and biophysical attributes of monoclonal antibodies. It also provides a representative test molecule for development of novel technologies for therapeutic protein characterization. The lifecycle management of NISTmAb includes a long-term stability verification to evaluate the homogeneity and stability for the first 3 lots (14HB-D001, 14HB-D-002, and 14HB-D-003) of this material. Initial certification to assign property values and confirm identification used a wide variety of analytical methods including UVVis spectrophotometry, size exclusion chromatography, capillary electrophoresis, dynamic light scattering, flow imaging, and peptide mapping. Reported here is a summary of these analytical methods and results for the 5-year stability verification (5YSV) for RM 8671 demonstrating the material is homogeneous and stable.


  • Open Access

    Attribute Analytics Performance Metrics from the MAM Consortium Interlaboratory Study

    by Trina Mouchahoir, John E. Schiel, Rich Rogers, Alan Heckert, Benjamin J. Place, Aaron Ammerman, Xiaoxiao Li, Tom Robinson, Brian Schmidt, Chris M. Chumsae, et al.

    The multi-attribute method (MAM) was conceived as a single assay to potentially replace multiple single-attribute assays that have long been used in process development and quality control (QC) for protein therapeutics. MAM is rooted in traditional peptide mapping methods; it leverages mass spectrometry (MS) detection for confident identification and quantitation of many types of protein attributes that may be targeted for monitoring. While MAM has been widely explored across the industry, it has yet to gain a strong foothold within QC laboratories as a replacement method for established orthogonal platforms. Members of the MAM consortium recently undertook an interlaboratory study to evaluate the industry-wide status of MAM. Here we present the results of this study as they pertain to the targeted attribute analytics component of MAM, including investigation into the sources of variability between laboratories and comparison of MAM data to orthogonal methods. These results are made available with an eye toward aiding the community in further optimizing the method to enable its more frequent use in the QC environment.


  • Open Access

    New Peak Detection Performance Metrics from the MAM Consortium Interlaboratory Study

    by Trina Mouchahoir, John E. Schiel, Rich Rogers, Alan Heckert, Benjamin J. Place, Aaron Ammerman, Xiaoxiao Li, Tom Robinson, Brian Schmidt, Chris M. Chumsae, et al.

    The Multi-Attribute Method (MAM) Consortium was initially formed as a venue to harmonize best practices, share experiences, and generate innovative methodologies to facilitate widespread integration of the MAM platform, which is an emerging ultra-high-performance liquid chromatography–mass spectrometry application. Successful implementation of MAM as a purity-indicating assay requires new peak detection (NPD) of potential process- and/or product-related impurities. The NPD interlaboratory study described herein was carried out by the MAM Consortium to report on the industry-wide performance of NPD using predigested samples of the NISTmAb Reference Material 8671. Results from 28 participating laboratories show that the NPD parameters being utilized across the industry are representative of high-resolution MS performance capabilities. Certain elements of NPD, including common sources of variability in the number of new peaks detected, that are critical to the performance of the purity function of MAM were identified in this study and are reported here as a means to further refine the methodology and accelerate adoption into manufacturer-specific protein therapeutic product life cycles.


  • Open Access

    Development of an LC-MS/MS peptide mapping protocol for the NISTmAb

    by Trina Mouchahoir, John E. Schiel

    Peptide mapping is a component of the analytical toolbox used within the biopharmaceutical industry to aid in the identity confirmation of a protein therapeutic and to monitor degradative events such as oxidation or deamidation. These methods offer the advantage of providing site-specific information regarding post-translational and chemical modifications that may arise during production, processing or storage. A number of such variations may also be induced by the sample preparation methods themselves which may confound the ability to accurately evaluate the true modification levels. One important focus when developing a peptide mapping method should therefore be the use of sample preparation conditions that will minimize the degree of artificial modifications induced. Unfortunately, the conditions that are amenable to effective reduction, alkylation and digestion are often the same conditions that promote unwanted modifications. Here we describe the optimization of a tryptic digestion protocol used for peptide mapping of the NISTmAb IgG1κ which addresses the challenge of balancing maximum digestion efficiency with minimum artificial modifications. The parameters on which we focused include buffer concentration, digestion time and temperature, as well as the source and type of trypsin (recombinant vs. pancreatic; bovine vs porcine) used. Using the optimized protocol we generated a peptide map of the NISTmAb which allowed us to confirm its identity at the level of primary structure. Peptide map of the NISTmAb RM 8671 monoclonal antibody. Tryptic digestion was performed using an optimized protocol and followed by LC-UV-MS analysis. The trace represents the total ion chromatogram. Each peak was mapped to peptides identified using mass spectrometry data.